


Erratum to: A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance

Yihua Xu¹ · Xiaofeng Zhou² · Brandon T. Suehs¹  · Abraham G. Hartzema³ · Michael G. Kahn⁴ · Yola Moride⁵ · Brian C. Sauer⁶ · Qing Liu² · Keran Moll¹ · Margaret K. Pasquale¹ · Vinit P. Nair¹ · Andrew Bate²

Published online: 2 July 2015
© Springer International Publishing Switzerland 2015

Erratum to: Drug Saf (2015)
DOI 10.1007/s40264-015-0297-5

An error was subsequently identified in the article, and the following correction should be noted:

Figures 2 and 3: The X-axis label in both figures was missing. The corrected figures should read:

The online version of the original article can be found under doi:[10.1007/s40264-015-0297-5](https://doi.org/10.1007/s40264-015-0297-5).

✉ Brandon T. Suehs
bsuehs6@humana.com

- ¹ Comprehensive Health Insights, Humana Inc.,
515 W. Market St., Louisville, KY 40202, USA
- ² Pfizer Inc., New York, NY, USA
- ³ College of Pharmacy, University of Florida,
Gainesville, FL, USA
- ⁴ Department of Pediatrics, University of Colorado,
Denver Anschutz Medical Campus, Aurora, CO, USA
- ⁵ Faculty of Pharmacy, Université de Montreal,
Montreal, QC, Canada
- ⁶ Division of Epidemiology, Department of Internal Medicine,
University of Utah, Salt Lake City, UT, USA

Fig. 2 Summary of High Dimensional Propensity Score based analytic procedure results: fixed risk period (30 days starting from index date). *AMI* acute myocardial infarction, *GI* gastrointestinal, *OMOP* Observational Medical Outcomes Partnership




Fig. 3 Summary of High Dimensional Propensity Score based analytic procedure results: variable risk period (drug exposure time plus 30 days). *AMI* acute myocardial infarction, *GI* gastrointestinal, *OMOP* Observational Medical Outcomes Partnership

